 | • レポートコード：GIR-105X13439 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、ペグフィルグラスチムバイオシミラーのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ペグフィルグラスチムバイオシミラーの種類別市場規模（化学療法治療、移植）、用途別市場規模（病院薬局、通信販売薬局、小売薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ペグフィルグラスチムバイオシミラーの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Novartis、Mylan、Coherus BioSciences、Mundipharma International、Biocon、Intas Pharmaceuticals、Pfizer、Dr Reddy’s Laboratories ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：化学療法治療、移植 ・用途別分析2016年-2026年：病院薬局、通信販売薬局、小売薬局 ・ペグフィルグラスチムバイオシミラーの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ペグフィルグラスチムバイオシミラーのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ペグフィルグラスチムバイオシミラーのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ペグフィルグラスチムバイオシミラーの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ペグフィルグラスチムバイオシミラーの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Pegfilgrastim Biosimilar market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Pegfilgrastim Biosimilar size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Pegfilgrastim Biosimilar market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Pegfilgrastim Biosimilar market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chemotherapy Treatment
Transplantation
Market segment by Application can be divided into
Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies
The key market players for global Pegfilgrastim Biosimilar market are listed below:
Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy’s Laboratories
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Pegfilgrastim Biosimilar product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Pegfilgrastim Biosimilar, with price, sales, revenue and global market share of Pegfilgrastim Biosimilar in 2018 and 2019.
Chapter 3, the Pegfilgrastim Biosimilar competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pegfilgrastim Biosimilar breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Pegfilgrastim Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Pegfilgrastim Biosimilar sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Pegfilgrastim Biosimilar Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Pegfilgrastim Biosimilar Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Chemotherapy Treatment
1.2.3 Transplantation
1.3 Market Analysis by Application
1.3.1 Overview: Global Pegfilgrastim Biosimilar Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Mail-Order Pharmacies
1.3.4 Retail Pharmacies
1.4 Global Pegfilgrastim Biosimilar Market Size & Forecast
1.4.1 Global Pegfilgrastim Biosimilar Sales in Value (2016-2026))
1.4.2 Global Pegfilgrastim Biosimilar Sales in Volume (2016-2026)
1.4.3 Global Pegfilgrastim Biosimilar Price by Type (2016-2026) & (US$/Unit)
1.5 Global Pegfilgrastim Biosimilar Production Capacity Analysis
1.5.1 Global Pegfilgrastim Biosimilar Total Production Capacity (2016-2026)
1.5.2 Global Pegfilgrastim Biosimilar Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Pegfilgrastim Biosimilar Market Drivers
1.6.2 Pegfilgrastim Biosimilar Market Restraints
1.6.3 Pegfilgrastim Biosimilar Trends Analysis
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Pegfilgrastim Biosimilar Product and Services
2.1.4 Novartis Pegfilgrastim Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Mylan
2.2.1 Mylan Details
2.2.2 Mylan Major Business
2.2.3 Mylan Pegfilgrastim Biosimilar Product and Services
2.2.4 Mylan Pegfilgrastim Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Coherus BioSciences
2.3.1 Coherus BioSciences Details
2.3.2 Coherus BioSciences Major Business
2.3.3 Coherus BioSciences Pegfilgrastim Biosimilar Product and Services
2.3.4 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Mundipharma International
2.4.1 Mundipharma International Details
2.4.2 Mundipharma International Major Business
2.4.3 Mundipharma International Pegfilgrastim Biosimilar Product and Services
2.4.4 Mundipharma International Pegfilgrastim Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Biocon
2.5.1 Biocon Details
2.5.2 Biocon Major Business
2.5.3 Biocon Pegfilgrastim Biosimilar Product and Services
2.5.4 Biocon Pegfilgrastim Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Intas Pharmaceuticals
2.6.1 Intas Pharmaceuticals Details
2.6.2 Intas Pharmaceuticals Major Business
2.6.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product and Services
2.6.4 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Pegfilgrastim Biosimilar Product and Services
2.7.4 Pfizer Pegfilgrastim Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Dr Reddy’s Laboratories
2.8.1 Dr Reddy’s Laboratories Details
2.8.2 Dr Reddy’s Laboratories Major Business
2.8.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product and Services
2.8.4 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Pegfilgrastim Biosimilar Sales by Manufacturer
3.1 Global Pegfilgrastim Biosimilar Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Pegfilgrastim Biosimilar Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Pegfilgrastim Biosimilar
3.4 Market Concentration Rate
3.4.1 Top 3 Pegfilgrastim Biosimilar Manufacturer Market Share
3.4.2 Top 6 Pegfilgrastim Biosimilar Manufacturer Market Share
3.5 Global Pegfilgrastim Biosimilar Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Pegfilgrastim Biosimilar Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Pegfilgrastim Biosimilar Market Size by Region
4.1.1 Global Pegfilgrastim Biosimilar Sales in Volume by Region (2016-2026)
4.1.2 Global Pegfilgrastim Biosimilar Revenue by Region (2016-2026)
4.2 North America Pegfilgrastim Biosimilar Revenue (2016-2026)
4.3 Europe Pegfilgrastim Biosimilar Revenue (2016-2026)
4.4 Asia-Pacific Pegfilgrastim Biosimilar Revenue (2016-2026)
4.5 South America Pegfilgrastim Biosimilar Revenue (2016-2026)
4.6 Middle East and Africa Pegfilgrastim Biosimilar Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Pegfilgrastim Biosimilar Sales in Volume by Type (2016-2026)
5.2 Global Pegfilgrastim Biosimilar Revenue by Type (2016-2026)
5.3 Global Pegfilgrastim Biosimilar Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Pegfilgrastim Biosimilar Sales in Volume by Application (2016-2026)
6.2 Global Pegfilgrastim Biosimilar Revenue by Application (2016-2026)
6.3 Global Pegfilgrastim Biosimilar Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Pegfilgrastim Biosimilar Sales by Type (2016-2026)
7.2 North America Pegfilgrastim Biosimilar Sales by Application (2016-2026)
7.3 North America Pegfilgrastim Biosimilar Market Size by Country
7.3.1 North America Pegfilgrastim Biosimilar Sales in Volume by Country (2016-2026)
7.3.2 North America Pegfilgrastim Biosimilar Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Pegfilgrastim Biosimilar Sales by Type (2016-2026)
8.2 Europe Pegfilgrastim Biosimilar Sales by Application (2016-2026)
8.3 Europe Pegfilgrastim Biosimilar Market Size by Country
8.3.1 Europe Pegfilgrastim Biosimilar Sales in Volume by Country (2016-2026)
8.3.2 Europe Pegfilgrastim Biosimilar Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Pegfilgrastim Biosimilar Sales by Type (2016-2026)
9.2 Asia-Pacific Pegfilgrastim Biosimilar Sales by Application (2016-2026)
9.3 Asia-Pacific Pegfilgrastim Biosimilar Market Size by Region
9.3.1 Asia-Pacific Pegfilgrastim Biosimilar Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Pegfilgrastim Biosimilar Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Pegfilgrastim Biosimilar Sales by Type (2016-2026)
10.2 South America Pegfilgrastim Biosimilar Sales by Application (2016-2026)
10.3 South America Pegfilgrastim Biosimilar Market Size by Country
10.3.1 South America Pegfilgrastim Biosimilar Sales in Volume by Country (2016-2026)
10.3.2 South America Pegfilgrastim Biosimilar Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Pegfilgrastim Biosimilar Sales by Type (2016-2026)
11.2 Middle East & Africa Pegfilgrastim Biosimilar Sales by Application (2016-2026)
11.3 Middle East & Africa Pegfilgrastim Biosimilar Market Size by Country
11.3.1 Middle East & Africa Pegfilgrastim Biosimilar Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Pegfilgrastim Biosimilar Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Pegfilgrastim Biosimilar Typical Distributors
12.3 Pegfilgrastim Biosimilar Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Pegfilgrastim Biosimilar Revenue by Type, (USD Million), 2021-2026
Table 2. Global Pegfilgrastim Biosimilar Revenue by Application, (USD Million), 2021-2026
Table 3. Novartis Basic Information, Manufacturing Base and Competitors
Table 4. Novartis Major Business
Table 5. Novartis Pegfilgrastim Biosimilar Product and Services
Table 6. Novartis Pegfilgrastim Biosimilar Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Mylan Basic Information, Manufacturing Base and Competitors
Table 8. Mylan Major Business
Table 9. Mylan Pegfilgrastim Biosimilar Product and Services
Table 10. Mylan Pegfilgrastim Biosimilar Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 12. Coherus BioSciences Major Business
Table 13. Coherus BioSciences Pegfilgrastim Biosimilar Product and Services
Table 14. Coherus BioSciences Pegfilgrastim Biosimilar Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Mundipharma International Basic Information, Manufacturing Base and Competitors
Table 16. Mundipharma International Major Business
Table 17. Mundipharma International Pegfilgrastim Biosimilar Product and Services
Table 18. Mundipharma International Pegfilgrastim Biosimilar Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Biocon Basic Information, Manufacturing Base and Competitors
Table 20. Biocon Major Business
Table 21. Biocon Pegfilgrastim Biosimilar Product and Services
Table 22. Biocon Pegfilgrastim Biosimilar Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Intas Pharmaceuticals Major Business
Table 25. Intas Pharmaceuticals Pegfilgrastim Biosimilar Product and Services
Table 26. Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Pfizer Basic Information, Manufacturing Base and Competitors
Table 28. Pfizer Major Business
Table 29. Pfizer Pegfilgrastim Biosimilar Product and Services
Table 30. Pfizer Pegfilgrastim Biosimilar Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Dr Reddy’s Laboratories Basic Information, Manufacturing Base and Competitors
Table 32. Dr Reddy’s Laboratories Major Business
Table 33. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product and Services
Table 34. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Pegfilgrastim Biosimilar Sales by Manufacturer (2019-2021e) & (K Units)
Table 36. Global Pegfilgrastim Biosimilar Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Pegfilgrastim Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Pegfilgrastim Biosimilar Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Pegfilgrastim Biosimilar Production Site of Key Manufacturer
Table 40. Pegfilgrastim Biosimilar New Entrant and Capacity Expansion Plans
Table 41. Pegfilgrastim Biosimilar Mergers & Acquisitions in the Past Five Years
Table 42. Global Pegfilgrastim Biosimilar Sales by Region (2016-2021e) & (K Units)
Table 43. Global Pegfilgrastim Biosimilar Sales by Region (2021-2026) & (K Units)
Table 44. Global Pegfilgrastim Biosimilar Revenue by Region (2016-2021e) & (USD Million)
Table 45. Global Pegfilgrastim Biosimilar Revenue by Region (2021-2026) & (USD Million)
Table 46. Global Pegfilgrastim Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 47. Global Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units)
Table 48. Global Pegfilgrastim Biosimilar Revenue by Type (2016-2021e) & (USD Million)
Table 49. Global Pegfilgrastim Biosimilar Revenue by Type (2021-2026) & (USD Million)
Table 50. Global Pegfilgrastim Biosimilar Price by Type (2016-2021e) & (US$/Unit)
Table 51. Global Pegfilgrastim Biosimilar Price by Type (2021-2026) & (US$/Unit)
Table 52. Global Pegfilgrastim Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 53. Global Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units)
Table 54. Global Pegfilgrastim Biosimilar Revenue by Application (2016-2021e) & (USD Million)
Table 55. Global Pegfilgrastim Biosimilar Revenue by Application (2021-2026) & (USD Million)
Table 56. Global Pegfilgrastim Biosimilar Price by Application (2016-2021e) & (US$/Unit)
Table 57. Global Pegfilgrastim Biosimilar Price by Application (2021-2026) & (US$/Unit)
Table 58. North America Pegfilgrastim Biosimilar Sales by Country (2016-2021e) & (K Units)
Table 59. North America Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units)
Table 60. North America Pegfilgrastim Biosimilar Revenue by Country (2016-2021e) & (USD Million)
Table 61. North America Pegfilgrastim Biosimilar Revenue by Country (2021-2026) & (USD Million)
Table 62. North America Pegfilgrastim Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 63. North America Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units)
Table 64. North America Pegfilgrastim Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 65. North America Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units)
Table 66. Europe Pegfilgrastim Biosimilar Sales by Country (2016-2021e) & (K Units)
Table 67. Europe Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units)
Table 68. Europe Pegfilgrastim Biosimilar Revenue by Country (2016-2021e) & (USD Million)
Table 69. Europe Pegfilgrastim Biosimilar Revenue by Country (2021-2026) & (USD Million)
Table 70. Europe Pegfilgrastim Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 71. Europe Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units)
Table 72. Europe Pegfilgrastim Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 73. Europe Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units)
Table 74. Asia-Pacific Pegfilgrastim Biosimilar Sales by Region (2016-2021e) & (K Units)
Table 75. Asia-Pacific Pegfilgrastim Biosimilar Sales by Region (2021-2026) & (K Units)
Table 76. Asia-Pacific Pegfilgrastim Biosimilar Revenue by Region (2016-2021e) & (USD Million)
Table 77. Asia-Pacific Pegfilgrastim Biosimilar Revenue by Region (2021-2026) & (USD Million)
Table 78. Asia-Pacific Pegfilgrastim Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 79. Asia-Pacific Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units)
Table 80. Asia-Pacific Pegfilgrastim Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 81. Asia-Pacific Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units)
Table 82. South America Pegfilgrastim Biosimilar Sales by Country (2016-2021e) & (K Units)
Table 83. South America Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units)
Table 84. South America Pegfilgrastim Biosimilar Revenue by Country (2016-2021e) & (USD Million)
Table 85. South America Pegfilgrastim Biosimilar Revenue by Country (2021-2026) & (USD Million)
Table 86. South America Pegfilgrastim Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 87. South America Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units)
Table 88. South America Pegfilgrastim Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 89. South America Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units)
Table 90. Middle East & Africa Pegfilgrastim Biosimilar Sales by Country (2016-2021e) & (K Units)
Table 91. Middle East & Africa Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units)
Table 92. Middle East & Africa Pegfilgrastim Biosimilar Revenue by Country (2016-2021e) & (USD Million)
Table 93. Middle East & Africa Pegfilgrastim Biosimilar Revenue by Country (2021-2026) & (USD Million)
Table 94. Middle East & Africa Pegfilgrastim Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 95. Middle East & Africa Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units)
Table 96. Middle East & Africa Pegfilgrastim Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 97. Middle East & Africa Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units)
Table 98. Direct Channel Pros & Cons
Table 99. Indirect Channel Pros & Cons
Table 100. Pegfilgrastim Biosimilar Typical Distributors
Table 101. Pegfilgrastim Biosimilar Typical Customers
List of Figures
Figure 1. Pegfilgrastim Biosimilar Picture
Figure 2. Global Pegfilgrastim Biosimilar Sales Market Share by Type in 2020
Figure 3. Chemotherapy Treatment
Figure 4. Transplantation
Figure 5. Global Pegfilgrastim Biosimilar Sales Market Share by Application in 2020
Figure 6. Hospital Pharmacies
Figure 7. Mail-Order Pharmacies
Figure 8. Retail Pharmacies
Figure 9. Global Pegfilgrastim Biosimilar Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 10. Global Pegfilgrastim Biosimilar Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. Global Pegfilgrastim Biosimilar Sales (2016-2026) & (K Units)
Figure 12. Global Pegfilgrastim Biosimilar Price by Type (2016-2026) & (US$/Unit)
Figure 13. Global Pegfilgrastim Biosimilar Production Capacity (2016-2026) & (K Units)
Figure 14. Global Pegfilgrastim Biosimilar Production Capacity by Geographic Region: 2020 VS 2021
Figure 15. Pegfilgrastim Biosimilar Market Drivers
Figure 16. Pegfilgrastim Biosimilar Market Restraints
Figure 17. Pegfilgrastim Biosimilar Market Trends
Figure 18. Global Pegfilgrastim Biosimilar Sales Market Share by Manufacturer in 2020
Figure 19. Global Pegfilgrastim Biosimilar Revenue Market Share by Manufacturer in 2020
Figure 20. Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. Top 3 Pegfilgrastim Biosimilar Manufacturer (Revenue) Market Share in 2020
Figure 22. Top 6 Pegfilgrastim Biosimilar Manufacturer (Revenue) Market Share in 2020
Figure 23. Global Pegfilgrastim Biosimilar Sales Market Share by Region (2016-2026)
Figure 24. Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2016-2026)
Figure 25. North America Pegfilgrastim Biosimilar Revenue (2016-2026) & (USD Million)
Figure 26. Europe Pegfilgrastim Biosimilar Revenue (2016-2026) & (USD Million)
Figure 27. Asia-Pacific Pegfilgrastim Biosimilar Revenue (2016-2026) & (USD Million)
Figure 28. South America Pegfilgrastim Biosimilar Revenue (2016-2026) & (USD Million)
Figure 29. Middle East & Africa Pegfilgrastim Biosimilar Revenue (2016-2026) & (USD Million)
Figure 30. Global Pegfilgrastim Biosimilar Sales Market Share by Type (2016-2026)
Figure 31. Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2016-2026)
Figure 32. Global Pegfilgrastim Biosimilar Price by Type (2016-2026) & (US$/Unit)
Figure 33. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2016-2026)
Figure 34. Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2016-2026)
Figure 35. Global Pegfilgrastim Biosimilar Price by Application (2016-2026) & (US$/Unit)
Figure 36. North America Pegfilgrastim Biosimilar Sales Market Share by Type (2016-2026)
Figure 37. North America Pegfilgrastim Biosimilar Sales Market Share by Application (2016-2026)
Figure 38. North America Pegfilgrastim Biosimilar Sales Market Share by Country (2016-2026)
Figure 39. North America Pegfilgrastim Biosimilar Revenue Market Share by Country (2016-2026)
Figure 40. United States Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Pegfilgrastim Biosimilar Sales Market Share by Type (2016-2026)
Figure 44. Europe Pegfilgrastim Biosimilar Sales Market Share by Application (2016-2026)
Figure 45. Europe Pegfilgrastim Biosimilar Sales Market Share by Country (2016-2026)
Figure 46. Europe Pegfilgrastim Biosimilar Revenue Market Share by Country (2016-2026)
Figure 47. Germany Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share by Region (2016-2026)
Figure 53. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Pegfilgrastim Biosimilar Revenue Market Share by Region (2016-2026)
Figure 56. China Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Korea Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Pegfilgrastim Biosimilar Sales Market Share by Type (2016-2026)
Figure 63. South America Pegfilgrastim Biosimilar Sales Market Share by Application (2016-2026)
Figure 64. South America Pegfilgrastim Biosimilar Sales Market Share by Country (2016-2026)
Figure 65. South America Pegfilgrastim Biosimilar Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East & Africa Pegfilgrastim Biosimilar Sales Market Share by Type (2016-2026)
Figure 69. Middle East & Africa Pegfilgrastim Biosimilar Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Pegfilgrastim Biosimilar Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Pegfilgrastim Biosimilar Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Egypt Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. South Africa Pegfilgrastim Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source
インフリキシマブ及びバイオシミラーの世界市場2018-2025 Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases. In 2018, the global Infliximab and biosimilar market size was xx million US$ and is forecast to xx million U…- インターフェロンバイオシミラーの世界市場2018-2025 This study researches the market size of Interferon Biosimilar, presents the global Interferon Biosimilar sales and revenue by companies, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.This report focuses on the key data information of Interferon Biosim…
- ベーチェット病気トリートメントの世界市場2018-2025 Behcet disease, also called Behcet's syndrome, is a rare disorder that causes blood vessel inflammation throughout your body.In 2018, the global Behcet Disease Treatment market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 h…
- 変形性関節症の治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Osteoarthritis (OA) is a type of joint disease that results from breakdown of joint cartilage and underlying bone. The most common symptoms are joint pain and stiffness. Initially, symptoms may occur only following exercise, but over time may become constant. Other symptoms may include joint swellin…
- 単純ヘルペスウイルス治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 The genital herpes treatment includes the use of drug types like Acyclovir that can treat herpes virus infections, including shingles. This medication does not cure herpes, but may prevent herpes sores or blisters. It is also used to treat outbreaks of genital herpes. In people with frequent outbrea…